Cargando…

Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis

Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonary exacerbations and improved FEV(1). Long-term effects are unknown. Objectives: Examine pulmonary outcomes among chronic azithromycin users compared with matche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichols, Dave P., Odem-Davis, Katherine, Cogen, Jonathan D., Goss, Christopher H., Ren, Clement L., Skalland, Michelle, Somayaji, Ranjani, Heltshe, Sonya L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049934/ https://www.ncbi.nlm.nih.gov/pubmed/31661302 http://dx.doi.org/10.1164/rccm.201906-1206OC

Ejemplares similares

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Azithromycin and the microbiota of cystic fibrosis sputum
por: Acosta, Nicole, et al.
Publicado: (2021)

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis
por: Paynter, Alex, et al.
Publicado: (2022)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Cystic fibrosis physicians’ perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States
por: Ramos, Kathleen J., et al.
Publicado: (2017)

Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis
por: Thornton, Christina S., et al.
Publicado: (2022)

Most Short Children with Cystic Fibrosis Do Not Catch Up by Adulthood
por: Marks, Margaret P., et al.
Publicado: (2021)

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response
por: Lam, John C, et al.
Publicado: (2015)

157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
por: VanDevanter, D., et al.
Publicado: (2021)

1481. Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients
por: Edwards, Brett, et al.
Publicado: (2018)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Stenotrophomonas maltophilia natural history and evolution in the airways of adults with cystic fibrosis
por: Izydorczyk, Conrad, et al.
Publicado: (2023)

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis
por: Skolnik, Kate, et al.
Publicado: (2015)

Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities
por: Acosta, Nicole, et al.
Publicado: (2020)

The natural history and genetic diversity of Haemophilus influenzae infecting the airways of adults with cystic fibrosis
por: Izydorczyk, Conrad, et al.
Publicado: (2022)

490: A prospective study to evaluate serologic and immune responses to SARS-COV-2 infection in persons living with cystic fibrosis: Canadian arm of the CAR-CF study
por: Blanchard, A., et al.
Publicado: (2021)

Erratum: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Publicado: (2019)

Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission
por: Izydorczyk, Conrad, et al.
Publicado: (2020)

Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis
por: Manor, Ohad, et al.
Publicado: (2016)

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
por: Gelfond, Daniel, et al.
Publicado: (2017)

When is cystic fibrosis not cystic fibrosis? The importance of appropriately classifying patients
por: Faro, Albert, et al.
Publicado: (2022)

Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice
por: Legssyer, Rachida, et al.
Publicado: (2006)

Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences
por: Eng, Alexander, et al.
Publicado: (2021)

Measuring the impact of an empiric antibiotic algorithm for pulmonary exacerbation in children and young adults with cystic fibrosis
por: Kennedy, Charles, et al.
Publicado: (2022)

Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?
por: Nichols, Dave P., et al.
Publicado: (2020)

Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape
por: Stanford, Gemma E., et al.
Publicado: (2021)

Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis
por: Woo, Taylor E., et al.
Publicado: (2018)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

433: Rationale and design of an international multicenter prospective study to evaluate serologic immune responses to SARS-CoV-2 infection in persons living with cystic fibrosis: The CAR-CF study
por: Hernandez, R., et al.
Publicado: (2021)

25: Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis
por: Hergenroeder, G., et al.
Publicado: (2021)

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
por: Mayer-Hamblett, Nicole, et al.
Publicado: (2021)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure
por: Hayden, HS, et al.
Publicado: (2020)

Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis
por: Gijs, Pieter-Jan, et al.
Publicado: (2023)

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist
por: Nichols, David P., et al.
Publicado: (2023)

The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies
por: Li, Kui, et al.
Publicado: (2022)

Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale
por: Gill, Eliana R., et al.
Publicado: (2023)

The Microbiome in Cystic Fibrosis Pulmonary Disease
por: Françoise, Alice, et al.
Publicado: (2020)

Hypoglycemia in Adults With Cystic Fibrosis During Oral Glucose Tolerance Testing
por: Hirsch, Irl B., et al.
Publicado: (2013)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ur5eo9attkvba1n0l2csg4n3qj